This website uses cookies to ensure you get the best experience on our website.
- Table of Contents
PLCG2 · Western blot design guide
PLCG2 Western Blot Planning Guide
Plan a PLCG2 Western blot around the catalog-observed 147.9 kDa band, image-backed A03572-1 evidence, HPA controls, and verified protocol records.
Evidence assembled July 2026 · For research use; verify linked source records and product datasheet before use
PLCG2 Western Blot Experimental Design Guide
Expected bands, documented protocol parameters, controls and antibodies — the at-a-glance facts below, then the full design guide.
Must know before running
| Expected band | 147.9 kDa | |
| Observed band | Not reported — verify product WB image | |
| Gel | 8-10% | |
| Positive control | Lung | |
| Negative control | Oral mucosa |
Important caveats
Reasons your observed band may differ from the expected size.
| ⓘ | Calculated mass | 147.9 kDa |
| ⓘ | Localization | Membrane raft |
| ⓘ | Processing / PTM | Record-dependent |
| ⓘ | Reactivity | Human |
Section 1
Real Curated PLCG2 Western Blot Protocols
Start with the molecular-weight rule, then compare verified publication-derived conditions.
| Sample / lysate | Appendix |
| Gel % | 8-10% |
| Load | 20-30 µg total protein per lane |
| Transfer | Wet/tank, extended transfer |
| Membrane | 0.45 µm PVDF |
| Blocking | 5% non-fat milk or 5% BSA in TBST |
| Primary | A03572-1 at datasheet starting dilution |
| Primary incubation | Overnight at 4 °C with gentle agitation |
| Secondary | Species-matched HRP conjugate at validated dilution |
| Wash | 3 × 5 min in TBST |
| Detection | Chemiluminescent substrate |
| Exposure | Bracket exposures to avoid saturation |
Section 2
What Is the Expected PLCG2 Western Blot Band Size?
Use the product-observed 147.9 kDa band as the primary planning value and retain the UniProt calculated mass as context.
| 147.9 kDa | Matches the authoritative product WB observation. |
| 147.9 kDa calculated | Use as UniProt context, not as a replacement observed band. |
| Unexpected additional signal | Do not assign identity without orthogonal positive/negative controls. |
💡Expected PLCG2 appearancePlan around 147.9 kDa and keep the calculated mass as supporting context.
| Catalog-observed band | 147.9 kDa; use this as the primary experimental expectation. |
| Calculated mass | 147.9 kDa from UniProt P16885; retain as context. |
| Gel selection | 8-10%; shared with the recommended protocol and poster. |
| Specificity check | Compare the lead HPA positive and negative controls with A03572-1. |
| Situation | Likely cause | Next action |
|---|---|---|
| 147.9 kDa | Matches the authoritative product WB observation. | Confirm with orthogonal controls and the linked product record. |
| Additional band | May reflect processing, modification, or non-specific signal. | Run a dilution series and compare positive/negative controls. |
| Weak signal | Target abundance or transfer may be limiting. | Verify transfer, increase positive-control abundance, and bracket exposure. |
Experiment evidence
Western blot images showing PLCG2 band
A03572-1 · PLCG2
← swipe / scroll for more images →
Real WB data behind the band-size expectations in this section.
Sample controls for PLCG2 Western blot
🧪Use Lung as the first positive-control candidate and Oral mucosa as the HPA Not detected negative candidate.
Positive control: Lung (High)
Negative control: Oral mucosa (Not detected)
HPA protein score determines control status; other expression data is supporting context only.
HPA tissue expression evidence for PLCG2
Comprehensive Human Protein Atlas IHC scoring per tissue. Rows are taken directly from the HPA tissue chart — click any row's HPA link to view the source.
Positive expression · recommended positive controls
| Tissue | Cell type | Level | Evidence | Source |
|---|---|---|---|---|
| Lung | Reported tissue cells | High | Protein (HPA) | HPA → |
| Skin | Reported tissue cells | High | Protein (HPA) | HPA → |
| Appendix | Reported tissue cells | High | Protein (HPA) | HPA → |
| Bone marrow | Reported tissue cells | High | Protein (HPA) | HPA → |
Section 3
Advanced PLCG2 Western Blot Tips
Deeper troubleshooting and optimisation questions for PLCG2, answered from its protein features.
Which band should guide the blot?
Use 147.9 kDa, the observation attached to the authoritative A03572-1 WB record.
How should calculated mass be interpreted?
Treat the UniProt calculated mass as context; it does not replace the catalog-observed 147.9 kDa expectation.
Which positive control should I start with?
Start with Lung, the lead HPA protein-expression candidate.
Which negative control is defensible?
Use Oral mucosa as an orthogonal HPA Not detected candidate.
Which gel should I use?
Use 8-10% consistently across the quick facts, protocol table, and poster.
What transfer method to use for PLCG2 Western blot?
Use the transfer method in the recommended protocol and verify transfer before blocking.
How should A03572-1 be started?
Start at the linked datasheet condition and run a three-point primary-antibody dilution test.
Which publication-derived protocols can I compare?
Compare only the supplied target-verified records: PMC12054200, PMC10082821, PMC5623081.
Boster reagents
PLCG2 Western Blot Reagents
Human-reactive PLCG2 Western blot reagents with authoritative product imagery.
Real WB data
Anti-PLCG 2/PLCG2 Antibody Picoband®
Cat # A03572-1
Only image-backed, WB-validated Human/Mouse/Rat recommendations from the prepared catalog evidence are shown.
Source: prepared picoband-wb product evidence; each card retains its own SKU, URL, observed band, and authoritative WB image.
References
- UniProt P16885
- Human Protein Atlas — PLCG2
- A03572-1 product record
- PMC12054200 — Exosomes derived from human amniotic mesenchymal stem cells promotes angiogenesis in hUVECs by delivering novel miRNA N-194.
- PMC10082821 — PLCG2 can exist in eccDNA and contribute to the metastasis of non-small cell lung cancer by regulating mitochondrial respiration.
- PMC5623081 — TLR2 Plays a Key Role in Platelet Hyperreactivity and Accelerated Thrombosis Associated With Hyperlipidemia.